Individual Study / IBIS-2

Integrated Biomarker and Imaging Study

Integrated Biomarker and Imaging Study

Initiatives -
IBIS-2 was a multi-center, randomized, double blind, placebo-controlled, parallel group study designed to examine the effects of once daily Darapladib Enteric Coated Tablet 160 mg on intermediate cardiovascular endpoints compared to placebo
Start Year
2008
Funding
GlaxoSmithKline
Visit IBIS-2

Members

Download
Investigators Contacts
  • Dr. Prof. Anthony A. Bavry
    UT Southwestern Medical Center

Design

Study design
Clinical trial cohort
Follow Up
The study evaluated safety and tolerability over the 1-year treatment duration

Marker Paper

Serruys PW, Garcia-Garcia HM, Buszman P, et al. for the IBIS-2 Investigators. Direct effects of the lipoprotein-associated phospholipase A2 inhibitor, darapladib, on human coronary atherosclerotic plaque. Circulation. 2008;118:1172-82.

Recruitment

Sources of Recruitment
  • Individuals

Number of participants

Number of participants
323
Number of participants with biosamples
Supplementary Information
Subjects aged 33-82 years from 10 countries in Europe (Denmark, Netherlands, Germany, Switzerland, Poland, Austria, Spain, Norway, Belgium, Czech Republic). placebo (n = 151)

Access

Availability of data and biosamples

Data
Biosamples
Other